Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ACET vs SLMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLMT Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 3–3 Matrix Metrics)

SLMT Overall Winner 6-Pillar Tally: ACET 2 – 2 SLMT (2 Tie) Matrix Metrics: ACET 3 – 3 SLMT

As of Nov 20, 2026, SLMT (SLMT) is the stronger overall head-to-head candidate over Adicet Bio, Inc. (ACET) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning). ACET carries a Unified Composite Score of 40.1/100 (SELL) at $2.14 (N/M Forward P/E, 0.0% operating margin), whereas SLMT carries 43.0/100 (HOLD) at $2.24 (N/M Forward P/E, -4271.3% operating margin).

  • Technical & Structure Timing Caution: ACET is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 13.6); meanwhile SLMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ACET vs SLMT
ACET NASDAQ
Adicet Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.14
-13.01% 1D
Market Cap $23.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.93β · 60% Vol
Unified Composite Score
40.1 / 100 SELL
Tech 25.0 Fund 44.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.9%), weak momentum, RSI 14
RSI-14: 13.6 · SMA20: $3.07 · SMA50: $5.23
SLMT US Equity Head-to-Head Winner
SLMT
Institutional Equity
$2.24
-13.85% 1D
Market Cap $28.6M
TTM Revenue $7.3M
Forward P/E N/M
Beta / 30D Vol 7.98β · 107% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 33.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.4%), weak momentum, RSI 33
RSI-14: 32.7 · SMA20: $3.03 · SMA50: $3.35

6-Pillar Scorecard Institutional Category Breakdown (ACET 2 – 2 SLMT)

Columns: Metric · ACET · SLMT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio 0.82x N/M
EV / Revenue N/M 3.9x
2. Growth & Scale SLMT
Revenue Growth (YoY) -100.0% +929.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $7.3M
Market Cap $23.0M $28.6M
3. Profitability & Quality ACET
Gross Margin N/A 100.0%
Operating Margin 0.0% -4271.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -85.9% -795.8%
4. Balance Sheet & Cash Flow ACET
Cash Generation (TTM) N/A -$310M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $15M Net Cash $10.73 Book/Sh · -795.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SLMT
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 230.4% (27th %ile) N/A (N/A)
Put/Call OI Skew 1.41x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Software - Infrastructure Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ACET (3) vs SLMT (3)
Institutional Metric ACET SLMT Criterion Row Edge
Market Capitalization
Scale
$23.0M $28.6M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% +929.8% Higher Growth SLMT
Operating Margin (TTM)
Profitability
0.0% -4271.3% Higher Margin ACET
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-85.9% -795.8% Higher ROE ACET
52-Week Range Position
Momentum
18% ($0–$10) 26% ($1–$7) Stronger Trend SLMT
Beta / 30D Volatility
Risk Regime
1.93β · 60% Vol 7.98β · 107% Vol Lower Realized Risk ACET
Unified Institutional Score
Composite Signal
40.1 / 100 (SELL) 43.0 / 100 (HOLD) Higher Composite SLMT
Trailing 12M Revenue (USD)
Operating Scale
N/A $7.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.82x PEG · N/M EV/Rev N/M PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($15M Net Cash) -$310M EBITDA ($10.73 Book/Sh · -795.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLMT +20.22 pp
ACET: -50.0% · SLMT: -29.78%
3M Horizon SLMT +29.81 pp
ACET: -75.96% · SLMT: -46.15%
6M Horizon SLMT +11.49 pp
ACET: -74.22% · SLMT: -62.73%
1Y Horizon ACET +332.07 pp
ACET: +270.76% · SLMT: -61.31%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ACET vs SLMT. Trailing 12-month operating profitability (ACET 0.0% vs SLMT -4271.3%) and valuation multiples (ACET N/M vs SLMT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ACET ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.9% · N/M
SLMT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.3M
Gross Margin100.0%
Op. Margin-4271.3%
ROE / Fwd P/E-795.8% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ACET BREAKDOWN
122d in phase · OBV DISTRIBUTION
Current IV 230.4%
IV Percentile 27th %ile
Put/Call OI Skew 1.41x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact ACET Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SLMT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ACET Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $23.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SLMT Moat Profile Cyclical / Execution-Driven Positioning
Software - Infrastructure Operator
Competes within the Software - Infrastructure value chain with $28.6M market capitalization and -4271.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ACET vs SLMT Key Questions & Quantitative Answers

As of Nov 20, 2026, SLMT (SLMT) is the stronger overall head-to-head candidate over Adicet Bio, Inc. (ACET) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Options & Positioning). ACET carries a Unified Composite Score of 40.1/100 (SELL) at $2.14 (N/M Forward P/E, 0.0% operating margin), whereas SLMT carries 43.0/100 (HOLD) at $2.24 (N/M Forward P/E, -4271.3% operating margin). Technical & Structure Timing Caution: ACET is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 13.6); meanwhile SLMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SLMT leads the Growth & Scale pillar: ACET posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SLMT at +929.8% YoY revenue growth and +0.0% YoY earnings growth on $7.3M TTM revenue (100.0% gross margin, -4271.3% operating margin). On trailing 12-month operating scale, ACET generates N/A in USD-normalized revenue versus $7.3M for SLMT. In operating R&D and SG&A reinvestment, ACET deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLMT.

ACET and SLMT trade at balanced relative valuation multiples. ACET trades at N/M Forward P/E, N/M Trailing P/E, 0.82x PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SLMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 3.9x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ACET (-85.9% ROE) versus SLMT (-795.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ACET carries 230.4% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 1.41x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.93β · 60% Vol realized risk). By comparison, SLMT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (7.98β · 107% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.